A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorGuangzhou Medical University
About this trial
This is a retrospective and prospective study planned to include NSCLC patients with Leptomeningeal metastasis (LM) and treated with antitumor therapy after 2018, from multiple centers such as the First Affiliated Hospital of Guangzhou Medical University, Guangdong Sanjiu Brain Hospital, etc., aiming to establish a database related to the treatment strategies of LM patients, and to evaluate the efficacy (eg. Overall Survival/Time to Failure) and safety of different treatment strategies of LM patients, etc., as well as the significance of concomitant testing in LM patients.
Eligibility criteria
Qualifiers
non-small cell lung cancer patients with Leptomeningeal metastases diagnosed after January 2018;
Patients who underwent antitumor therapy after diagnosis of LM.
Disqualifiers
Patients with small cell lung cancer components;
complicated with tumors other than non-small cell lung cancer.
Trial design
Treatments tested in this trial
- Not applicable- observational study
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov